stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) EBITDA
CRISPR Therapeutics AG's EBITDA for fiscal 2025 was −$645.1M, compared with −$447.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$513.8M. Over the past ten years it has ranged from −$649.0M (fiscal 2022) to $391.5M (fiscal 2021); the current reading is higher than 18% of that period. CRISPR Therapeutics AG ranks 577th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$645.1M | — |
| FY2024 | −$447.3M | — |
| FY2023 | −$202.7M | — |
| FY2022 | −$649.0M | — |
| FY2021 | $391.5M | — |
| FY2020 | −$343.4M | — |
| FY2019 | $51.5M | — |
| FY2018 | −$155.4M | — |
| FY2017 | −$61.6M | — |
| FY2016 | −$67.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$125.8M | — |
| Jun 2026 | −$113.0M | — |
| Mar 2026 | −$125.9M | — |
| Dec 2025 | −$149.1M | — |
| 40 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TVTX Travere Therapeutics, Inc. compare | −$83.5M |
| MANE Veradermics Incorporated compare | −$88.4M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| DNTH Dianthus Therapeutics, Inc. compare | −$244.2M |
| ERAS Erasca, Inc. compare | −$302.6M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| CRSP CRISPR Therapeutics AG | −$513.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement